Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neihulizumab - AbGenomics

Drug Profile

Neihulizumab - AbGenomics

Alternative Names: AbGn-168; AbGn-168H; Antibody-168

Latest Information Update: 11 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbGenomics Corporation
  • Developer AbGenomics Corporation; Boehringer Ingelheim; Stanford University
  • Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; P-selectin ligand protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Psoriatic arthritis; Ulcerative colitis
  • Phase I Graft-versus-host disease; Type 1 diabetes mellitus
  • Discontinued Plaque psoriasis

Most Recent Events

  • 30 Oct 2019 AbGenomics plans a phase I trial for Graft-versus-host disease (Prevention) in USA (IV, Infusion) (NCT04144036)
  • 11 Dec 2018 Phase I development for Graft-versus-host disease is ongoing (AbGenomics pipeline, December 2018)
  • 11 Dec 2018 AbGenomics plans a clinical trial for Psoriatic arthritis (Biologic refractory, Combination therapy with leiolizumab) (AbGenomics pipeline, December 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top